This observational study (n=200) will examine how the brain's information processing changes during and after the administration of serotonergic psychedelics, including psilocybin, DMT, and LSD, in individuals with and without mental illness who are receiving these substances through clinical trials at Yale University.
Status: Recruiting
Start date: 2024-12-12
Not Applicable
Open
200 participants
Observational
This observational pilot study (n=10) will examine salivary oxytocin levels during a single dose of LSD as part of psychedelic-assisted psychotherapy (PAP) for anxiety disorders or depression.
Status: Recruiting
Start date: 2024-08-05
Not Applicable
Open
10 participants
Observational
This randomised, double-dummy, triple-blind, placebo-controlled, parallel groups trial (n=90) investigates the effects of LSD microdosing (2-20μg) in patients with major depressive disorder (MDD) compared to an active placebo.
Status: Not yet recruiting
Start date: 2024-03-11
Phase II
Blinded
90 participants
Interventional
This randomised, double-blind, placebo-controlled crossover trial (n=20) conducted by the University Hospital in Basel, Switzerland, aims to investigate the effects of ketanserin, olanzapine, and lorazepam administered after LSD (150µg) on the acute response to LSD in healthy subjects.
Status: Recruiting
Start date: 2024-02-01
Phase I
Blinded
20 participants
Interventional
This randomized, double-blind, placebo-controlled trial (n=40) aims to investigate the effects of lysergic acid diethylamide (LSD) on neuroplasticity in healthy human subjects.
Status: Recruiting
Start date: 2022-05-02
Phase I
Blinded
40 participants
Interventional
This observational cohort study (n=100) aims to assess the efficacy of psychedelics, including psilocybin, MDMA, LSD, and ketamine, for improving measures of wellness.
Status: Active, not recruiting
Start date: 2022-07-19
Not Applicable
Open
100 participants
Observational
This double-blind, placebo-controlled crossover trial (n=60) investigates the effects of LSD on neural synchrony, prosocial behavior, and relationship quality in healthy romantic couples.
Status: Recruiting
Start date: 2023-01-01
Phase I
Blinded
60 participants
Interventional
This double-blinded, placebo-controlled crossover trial (n=30) aims to investigate the effects of low doses of LSD (10-20μg) on behavioural and neural indicators of feedback and feedforward signalling in perceptual decision-making.
Status: Recruiting
Start date: 2024-02-20
Not Applicable
Blinded
30 participants
Interventional
This double-blind, placebo-controlled trial (n=65) will assess the efficacy and safety of LSD (25μg) every 3 days for 3 weeks versus placebo in treating chronic cluster headaches (CCH).
Status: Not yet recruiting
Start date: 2024-01-01
Phase II
Blinded
64 participants
Interventional
This interventional trial (n=27), led by Maastricht University with sponsorship from the Department of Psychology and Neurosciences, involves exploring the dose-response relationship in LSD-induced subjective and cognitive effects in healthy volunteers.
Status: Not yet recruiting
Start date: 2018-05-01
Not Applicable
Blinded
27 participants
Interventional
This interventional trial (n=60), conducted by the University Maastricht (UM), investigates the effects of psilocybin (12mg/70kg) on cognitive flexibility, specifically divergent thinking and goal-directed behaviour.
Status: Planned
Start date: 2017-05-01
Not Applicable
Blinded
60 participants
Interventional
This interventional trial (n=24) conducted by Maastricht University, with support from Mind Medicine Inc. (MindMed), aims to investigate the effects of three small morning and evening doses of LSD (20µg) on mood, sleep parameters, neuroplasticity, cognitive performance, emotion regulation, markers of well-being, cortisol, and endocannabinoid levels in healthy volunteers.
Status: Recruiting
Start date: 2021-12-01
Not Applicable
Blinded
24 participants
Interventional
This double-blind, randomized trial (n=60) conducted by Maastricht University Department of Psychology and Neurosciences, explores the effects of repeated doses of LSD (15µg) on mood, cognition, and neuroplasticity in healthy volunteers.
Status: Completed
Start date: 2020-02-03
Not Applicable
Blinded
53 participants
Interventional
This open-label pilot trial (n=20) assesses the tolerability and feasibility of LSD microdosing in patients with major depressive disorder (MDD).
Status: Recruiting
Start date: 2023-08-14
Phase II
Open
20 participants
Interventional
This randomized, quadruple-blind, crossover trial (n=20) conducted by the University Hospital in Basel, Switzerland, aims to investigate the effect of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) administered after LSD (150 µg) intake on the acute response to LSD in healthy subjects.
Status: Recruiting
Start date: 2024-02-01
Phase I
Blinded
20 participants
Interventional
This randomized, double-blinded, crossover trial (n=30) aims to characterise the effects of low doses of LSD on behavioural and neural indicators of feedback and feedforward signalling in perceptual decision-making.
Status: Recruiting
Start date: 2024-02-20
Not Applicable
Blinded
30 participants
Interventional
This early-phase, interventional trial (n=40) investigates LSD occupancy at the serotonin 2A receptor (5-HT2AR) in the human brain. Healthy participants aged 18-75 will receive a single dose of LSD ranging from 25 to 200 micrograms equivalent freebase.
Status: Recruiting
Start date: 2023-11-08
Phase I
Open
40 participants
Interventional
This Phase I study explored the safety, tolerability, pharmacokinetics, and pharmacodynamics of low doses of Lysergic Acid Diethylamide (LSD) ranging from 50 µg to 100 µg.
Status: Completed
Start date: 2015-10-20
Phase I
Open
32 participants
Interventional
This randomized, double-blind, placebo-controlled trial (n=80) will study the effects of repeated microdoses of lysergic acid diethylamide (LSD) on creativity and brain activity in healthy adult males. Participants will receive either 10 µg of LSD or a placebo, dissolved in water in 1 ml oral syringes, taken once every three days for a total of 14 doses over a 41-day regimen.
Status: Completed
Start date: 2019-11-19
Phase I
Blinded
80 participants
Interventional
This randomized, double-blind, active-placebo controlled trial (n=60) will evaluate the effects of LSD on psychosocial distress in patients suffering from an end-stage fatal disease with a life expectancy of 12 weeks to 2 years.
Status: Not yet recruiting
Start date: 2023-09-01
Phase II
Blinded
60 participants
Interventional
This open-label pilot trial (n=20) aims to evaluate the tolerability and feasibility of LSD microdosing in patients with major depressive disorder (MDD).
Status: Recruiting
Start date: 2023-08-14
Phase II
Open
20 participants
Interventional
This double-blind, placebo-controlled feasibility trial (n=40) investigates Psychedelic Microdosing-Assisted Meaning-Centred Psychotherapy (PA–MCP) in advanced-stage cancer patients. Led by Dr Lisa Reynolds at The University of Auckland, the study aims to evaluate the effects of LSD microdosing (starting at 8 mcg, 2 times a week for 6 weeks) alongside Meaning-Centred Psychotherapy.
Status: Not yet recruiting
Start date: 2023-06-01
Phase II
Blinded
40 participants
Interventional
This trial (n=48) will follow therapists as they embark on their own psychedelic experiences. The trial's focus is on the benefits and risks to both the therapists and the patients (and their interaction).
Status: Not yet recruiting
Start date: 2022-12-01
Not Applicable
Open
48 participants
Interventional
This double-blind, randomised study (n=65) will investigate if every third-day mini-dosing (25μg) of LSD for three weeks (7x dosing) alleviates chronic cluster headaches (CCH).
Status: Not yet recruiting
Start date: 2023-05-01
Phase II
Blinded
65 participants
Interventional
This double-blind study (n=128) will investigate if LSD (150-250μg, 2x) will be effective in treating alcoholism (AUD). This will be compared to an 'active' placebo of 10μg LSD. The study, when conducted, will be the largest modern study of LSD for AUD.
Status: Not yet recruiting
Start date: 2023-01-01
Phase II
Blinded
128 participants
Interventional
This is a Phase II, multi-centre, randomized, double-blind, parallel-group, dose-finding study to assess the effect of four doses of MM-120 (25, 50, 100 or 200 μg LSD freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).
Status: Recruiting
Start date: 2022-06-27
Phase II
Blinded
200 participants
Interventional
This study measures the safety and efficacy of repeated low dose MM-120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled trial.
Status: Completed
Start date: 2021-12-17
Phase II
Blinded
52 participants
Interventional
The aim of the present study is to assess the neuronal correlates of alterations in waking consciousness pharmacologically induced by a 5-hydroxytryptamine (HT)2A receptor agonist in healthy subjects using functional magnetic resonance imaging (fMRI).
Status: Completed
Start date: 2014-12-01
Phase I
Open
24 participants
Interventional
The aim of the study is to assess whether SERT inhibition reduces expression of the gene coding for the 5-HT2A receptor and the response to LSD.
Status: Not yet recruiting
Start date: 2022-03-01
Phase I
Blinded
24 participants
Interventional
TD-0148A is a non-hallucinogenic second-generation Lysergic Acid Diethylamide (“LSD”) derivative molecule that mimics the projected therapeutic potential of LSD in the treatment of disorders such as depression, PTSD, and migraines.
Status: Planned
Start date: 2023-1-1
Phase I
Open
10 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
